Treating Idiopathic Male Infertility with a Combination of Tamoxifen Citrate and a Natural Compost with Antioxidant and Androgen-Mimetic Action

Iacono F, Prezioso D, Ruffo A*, Di Lauro G, Illiano E, Romeo G and Romis L
Department of Urology, University “Federico II” of Naples, Italy

Abstract

Background: We investigated the efficacy of a combination therapy with tamoxifen citrate and a natural composite containing Tribulus terrestris, alga Ecklonia bicyclis and polymers of d-glucosamine and n-acetyl d-glucosamine in treating male idiopathic infertility.

Methods: In this prospective, randomized double blind, placebo-controlled study, we enrolled ninety infertile men at our department of urology at University Federico II of Naples. Mean age was 29.2 ± 7.8 (± SD). Inclusion criteria consisted of the repeated exhibition of oligoasthenozoospermia (OA) without detectable cause (unexplained OA). Patients were randomly assigned to three treatment groups: Group A (n=30) receiving tamoxifen citrate (20 mg/day) and a natural composite with an antioxidant and androgen-mimetic action (150 mg of alga Ecklonia Bicyclis, 396 mg of Tribulus terrestris and 144 mg of polymers of d-glucosamine and n-acetyl d-glucosamine); Group B (n=30) receiving tamoxifen citrate (20 mg/day) and Group C receiving placebo (n=30). We evaluated the number of spontaneous pregnancies, sperm volume, concentration, sperm total motility, sperm forward progressive motility, normal sperm morphology.

Results: After 6 months of therapy the number of spontaneous pregnancies was markedly higher in the Group A (13 pregnancies, 33.3%) than the other two groups: Group B (6 pregnancies, 20%) and Group C (4 pregnancies, 13.3%). Sperm concentration improved in the Group A from a mean 8.49 × 10^6 cells/ml ± 5.57 at baseline to 22.1 × 10^6 cells/ml ± 1.63 (p ≤ 0.001). In the Group B there was an improvement from a mean 7.98 × 10^6 at baseline to 14.43 × 10^6 cells/ml ± 3.43 (p=0.002). Group C did not see a statistically significant improvement of sperm number, from a concentration of 9.65 × 10^6 cells/ml ± 6.54 to 10.53 × 10^6 cells/ml ± 8.5 (p=0.0025). In Group A, sperm total motility improved from 31% ± 11% at baseline to 40% ± 14% (p=0.007) whilst the forward progressive motility slightly improved from 5% ± 3% to 9% ± 4% (p=0.0034). In the group B and C, there were not reported statistically significant changes of motility.

Conclusions: The combination therapy with tamoxifen citrate and the natural compound with an androgen-mimetic and antioxidant action leads to a higher incidence of pregnancy rates and gives a statistically significant improvement of semen parameters comparing with the single use of tamoxifen citrate and with the control group.

Keywords: Male infertility; Antioxidant; Oligospermia; Oligoasthenozoospermia (OA); Tamoxifen citrate

*Corresponding author: Ruffo A, Department of Urology, University “Federico II” of Naples Via S. Pansini, 5 – 80131 Naples , Italy, Tel: +39 3339323372, +39 0817462607; E-mail: antonio.ruffo7@gmail.com

Received January 28, 2013; Accepted March 13, 2013; Published March 31, 2013


Copyright: © 2013 Iacono F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Of the many causes of male infertility, oxidative stress (OS) has been shown to affect the fertility status and for this reason it has been widely studied in the past few years.

Spermatozoa, like all other aerobic cells are particularly susceptible to oxidative stress induced damage because of the large polyunsaturated fat content in their membranes. Men with high ROS may have a lower fertility potential compared to those with low ROS [5].

High levels of reactive oxygen species in semen have been correlated with reduced sperm motility and damage to sperm nuclear DNA [5].

For example, IL-1 α, IL-1 β and tumor necrosis factor α (TNF-α), stimulate sperm peroxidation by increasing ROS generation [6]; IL-6 has been shown to play a pivotal role in the induction of capacitation and the acrosomal reaction in sperm [7]. However, high levels of cytokines in the semen have been correlated with sperm injury, most notably cell membrane lipid peroxidation in the presence of elevated IL-6 [6,8]. Further, increased levels of IL-6 have also been noted in the seminal fluid of infertile men [9].

Also, IL-1, IL-6, IL-8 and TNF have all been shown to induce increased ROS production, leading to increased sperm cell membrane lipid peroxidation [6,8,10].

Interferon gamma (IFN-γ) and TNFα have been shown to decrease the motility of spermatozoa.

This condition is common in cases of genitourinary tract infections and inflammation, in which oxidative mechanism produce the oxidative stress [11].

Antioxidants in seminal plasma are the most important form of protection available to spermatozoa against ROS [6,12].

That is why it is commonly used to prescribe antioxidant oral therapy for the idiopathic male oligoasthenospermia to decrease oxidative stress and improve fertility.

Antiestrogens have been one of the oldest and most commonly prescribed forms of therapy for idiopathic male infertility. These drugs inhibit the negative feedback effect of estrogen on the hypothalamus and pituitary, increasing endogenous gonadotropin secretion.

Antiestrogen therapy was reported to yield pregnancy rates ranging from 20%–40% following 6-9 months of therapy [13] from the hypothalamus and FSH and LH secretion directly from the pituitary, increasing their levels, thereby stimulating spermatogenesis [14].

Pregnancy rates following varicocelectomy were approximately 40% [15].

Methods

This is a prospective, randomized double blind, placebo-controlled study. We enrolled ninety infertile men attending our department of urology at University Federico II of Naples. Mean age of male partner was 29.2 ± 7.8 [± SD] while female partner mean age was 27.4 ± 6.8 [± SD]. We included a minimum of 1 year of regular unprotected sexual activity without achieving pregnancy. Inclusion criteria consisted of the repeated exhibition of oligoasthenozoospermia without detectable cause (unexplained OA). We evaluated the number of spontaneous pregnancy, sperm volume and concentration, sperm total motility, forward progressive motility and normal morphology.

Exclusion criteria included cases with known etiology or leukocytospermia, and altered testicular volume, varicocele (as detected by clinical examination and ultrasonography) or an abnormal FSH level. Couples with combined male and female factors were excluded. Patients signed a informed consent explaining the nature of the study, the possibility of treatment failure, and possible side effects.

They underwent a clinical evaluation including history taking, general examination, and genital examination for possible causes of infertility. Investigations for the male partner included semen analysis according to World Health Organization criteria [16]. Only couples with no female factor infertility were included in the study.

Patients were blindly randomized into three groups: Group A (time of infertility 2.4 ± 1.2 years [± SD]) receiving a combination of an antiestrogen [tamoxifen citrate 20 mg/day] and a natural composite with an antioxidant and androgen-mimetic action [150 mg of alga Ecklonia Bicyclus, 396 mg of Tribulus terrestris and 144 mg of polymers of d-glucosamine and n-acetyl d-glucosamine (Tradamix®); n=30; Group B (time of infertility 2.2 ± 1.1 years [± SD)] receiving tamoxifen citrate (n=30) and Group C (time of infertility 1.9 ± 1.0 years [± SD] receiving placebo (n=30). Treatment was continued for 6 months. All statistical measurements were performed using ANOVA tests. We wanted to have a level of significance with p<0.05.

Results

After 6 months of therapy the cumulative number of pregnancy was markedly higher in the Group A (13 pregnancies, 33.3%) then the other two groups: Group B (6 pregnancies, 20%) and Group C (4 pregnancies, 13.3%). This difference is statistically significant (p=0.023) (Table 1).

In the tables 1 and 2, are reported the changing in semen parameters before and after treatment in the three groups.

Sperm concentration significantly improved in the Group A from a mean 8.49 × 10⁶ cells/ml ± 5,57 at baseline to 22.1×10⁶ cells/ml ± 1,63 (p ≤ 0.001) comparing with the tamoxifen recipients (Group B) where the was an improvement from a mean 7.98 × 10⁶ at baseline to 14.43 × 10⁶ cells/ml ± 3.43 (p=0.002). Group C had an improvement of sperm number, from a concentration of 9.65 × 10⁶ cells/ml ± 6.54 to 10.53×10⁶ cells/ml ± 8.5 (p=0.0025) (Table 2A).

<table>
<thead>
<tr>
<th>Group</th>
<th>Cases</th>
<th>Volume (ml)</th>
<th>Count (× 10⁶)</th>
<th>TM (%)</th>
<th>FPM (%)</th>
<th>ABF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamoxifen</td>
<td>30</td>
<td>2.2</td>
<td>7.98</td>
<td>30</td>
<td>8</td>
<td>39</td>
</tr>
<tr>
<td>Tradamix®</td>
<td></td>
<td>2.5</td>
<td>9.65</td>
<td>29</td>
<td>6</td>
<td>37</td>
</tr>
<tr>
<td>Placebo</td>
<td>30</td>
<td>2.7</td>
<td>21.6</td>
<td>35</td>
<td>5</td>
<td>38</td>
</tr>
</tbody>
</table>

Table 1: Pregnancy rates in the 3 Groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Volume (ml)</th>
<th>Count (× 10⁶)</th>
<th>TM (%)</th>
<th>FPM (%)</th>
<th>ABF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamoxifen</td>
<td>2.4</td>
<td>8.49</td>
<td>31</td>
<td>5</td>
<td>37</td>
</tr>
<tr>
<td>Tradamix®</td>
<td></td>
<td>2.2</td>
<td>7.98</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>Placebo</td>
<td>2.5</td>
<td>9.65</td>
<td>29</td>
<td>6</td>
<td>37</td>
</tr>
</tbody>
</table>

Table 2B: Semen parameters after treatment in the 3 Groups.
In Group A sperm total motility improved from 31% ± 11% at baseline to 40% ± 14% (p=0.007) whilst the forward progressive motility slightly improved from 5% ± 3% to 9% ± 4% (p=0.0034). For the other two groups there were not reported statistically significant changes of motility (Table 2B).

Seminal volume did not change after the treatment in the Group A (2.47 ± 1.4 at baseline, 2.9 ± 1.6 at 6 months) and no difference from Group B and placebo recipients (Group C) were observed.

No remarkable difference in sperm form was reported.

Discussion

In this study, we evaluated the effectiveness of the combination of tamoxifen citrate and this natural compost in treating idiopathic male infertility. Combination therapy for male infertility has been evaluated by other investigators. Comhaire et al. [17] studied 30 men with infertility and female partners with no demonstrable cause of infertility who received conventional treatment according to the guidelines of the World Health Organization [16], and either a strong antioxidant, astaxanthin (16 mg/day), or a placebo for 3 months. The results revealed total pregnancy rates of 10.5% among the placebo cases, compared with 54.5 in the active treatment arm (p=0.028).

Our results (Table 1) are similar with the findings of Adamopolous et al. [18,19]. A recent short review assessing evidence-based treatments for male infertility show many methodological difficulties with these works [20] given by the short duration of most of these studies. Although married couples are allowed 1 year of unprotected intercourse to conceive before a diagnosis of infertility is made, most studies allow only an average of 3 months of observation, even if seminal parameters improve. Results of medical treatment in terms of cumulative pregnancy rates may differ if the observation period is long enough. This has been clearly suggested by the improved pregnancy rate after 6 months shown in our work as well as by Adamopolous et al. [18] and Ghanem et al. [20]. This study suggests that combination of an antiestrogen with a substance with an antioxidant and androgen-mimetic action is a valid therapy for men with oligoasthenozoospermia.

This composite (TradamiX®) contains these three compounds: alga Ecklonia bicyclis, Tribulus terrestris and polymers of d-glucosamine and n-acetyl-d-glucosamine.

Alga bicyclis is a macro algae widely distributed along the Pacific coast of central Japan and Korea where, when conditions are suitable, forming extensive underwater meadows (kelp forests), often mixed. The biological properties attributed to these species are instead traced to the presence of particular secondary metabolites also known as the phlorotannins and made the union of various units of the same monomer, the 1,3,5-triiodossi phenol or phloroglucinol. So far a dozen such compounds has been identified, the most important of which are shown in the figures [21-24]. Right now, more than 20,000 new compounds have been isolated from marine organisms; numbers of these naturally occurring derivatives are developed as potential candidates for pharmaceutical applications. Phlorotannins are secondary metabolites distributed in a variety of plants. They are phloroglucin derivatives with a variety of biological functions in vitro and in vivo, such as a strong radical scavenging and antioxidant action [25,26].

Ecklonia cava radical scavenger activity 10-100 powerful than any other polyfenol terrestris plants, including green tea catechins, which have only 3-4 fenolic and rings that are commonly considered among the most effective antioxidant molecules. Common polyphenols are soluble in water also and have a relatively short half-life introduced into the body. All phlorotannins had antioxidant properties in vitro, especially, bieckol, dieckol and phlorofucofuroeckol [26] (Figures 1-3).

Inflammatory cells might generate and release a large number of inflammatory mediators: for example, proinflammatory cytokines and inflammatory cytokines, such as interleukins [27-30], TNF-α [27-30], p53 [31], cytochrome P-450 [27-32] and NADPH-cytochrome P-450 [27-31] causing abnormal metabolism of the hypoxanthine/xanthine oxidase system and the xanthine/xanthine oxidase system, producing many abnormal metabolites [27-33].

These inflammatory cells and reactions might also activate and release a large amount of COX-2 [27-29] transcription NF-κ B [27-29] iNOS, and an amount of inflammatory oxidants and other chemokines [27,34,35] and without question, they might induce, generate and release a large number of O₂⁻, ·OH, NO and other free radicals, as well as O₂, H₂O₂, and other ROS [27,28,31,33,34]. Excessive free radicals and ROS, as strong oxidants, might affects replication and transcription.
and PGE2 production in a concentration-dependent manner. Jung et al. revealed that dieckol inhibits LPS-induced NO inhibiting the formation of prostaglandin E2, a powerful inflammatory caused by ROS and in part by slowing the gaming lipoxygenase and response inflammatory, partially neutralizing the inflammatory damage such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α. significantly reduced the generation of proinflammatory cytokines, and neuroprotective actions of EC in BV2 microglia [40]. It also These findings provide mechanistic insights into the anti-inflammatory activation as well as reactive oxygen species (ROS) production [39]. Alga ecklonia treatment significantly reduced NF-kB translocation and DNA-binding in LPS-stimulated BV2 microglia [39] causing [38,39]. Alga ecklonia treatment significantly reduced NF-kB translocation and DNA-binding in LPS-stimulated BV2 microglia [39] and p38 mitogen-activated protein kinases (MAPKs) activation [37].

Phlorotannins suppresses the induction of cytokines by LPS, as well as iNOS and COX-2 expression, by blocking NF-kappaB and MAPK activations well as reactive oxygen species (ROS) production [39]. These findings provide mechanistic insights into the anti-inflammatory and neuroprotective actions of EC in BV2 microglia [40]. It also significantly reduced the generation of proinflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α.

Kim et al. revealed extracts reduced the concentrations of IL-4 and IL-5 by 66% and 84%, respectively, and resulted in a 73% reduction in the secretion of TNF-α [35].

The second compound contained in the composite used in this therapy is Tribulus terrestris. This plant native of India, but now present in most of North America has a weed Active ingredients: protodioscin. The plant contains also flavonoids, alkaloids and amides, although its properties seem to be completely attributed to protodioscin (Figure 4).

The parts used are the seeds and fruits, and, more generally, the aerial parts of the plant. The protodioscin is a steroidal saponin, which is about 45% of the extract obtained from aerial parts of Tribulus terrestris (Figure 4). The substance is able to increase the endogenous production of testosterone, dihydrotestosterone, a hormone luteinizing hormone (LH), dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) [40]. Because of these effects in experimental animals there is an increase in spermatogenesis and the frequency of matches [41]. In the rabbit in particular has been shown that the compound stimulates the release of nitric oxide (NO) by vascular endothelium of the corpora cavernosa thereby having a pro-erectile effect [41]. The mechanism behind this effect appears to involve the pathway of steroid hormones [41]. Although humans protodioscin is used for the treatment of erectile dysfunction [42, 43].

A study conducted on 150 Italian patients affected by erectile dysfunction treated with the same composite containing Tribulus terrestris, alga Ecklonia bicyclis and polymers of d-glucosamine and n-acetyl-d-glucosamine showed and improvement of 28% of the testosterone levels from a baseline mean value of 5.3 ± 1.1 ng/ml to 6.8 ± 1.6 (p<0.01) post treatment [44].

Polymers of d-glucosamine and n-acetyl-d-glucosamine acts on as a nitric oxide synthetase (NOS) stimulator [44] (Figure 5).

Nitric oxide (NO) is a free radical generated from the oxidation of L-arginine to L-citrulline by reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent nitric oxide synthase (NOS). Nitric oxide is diffusible, multifunctional, and acts as a transcellular messenger, being implicated in numerous physiologic and pathologic conditions [45].

Nitric oxide, at physiologic concentrations, is relatively nonreactive, but most of its actions are mediated by activation of cyclic guanosine monophosphate production [46]. It is reported that NO modulates sexual and reproductive functions in mammalian species [47,48]. The presence of NO in seminal plasma has been confirmed [49]. The source of NO in seminal plasma may be either male reproductive organs or macrophages [50,51]. The production of NO in human and animal sperm has also been reported [50,51].

Nitric oxide is reported to be a novel mediator of sperm function [52]. It has both positive and negative effects. The positive modulation reflects the role of NO in physiologic processes like sperm capacitation [52] and acrosome reaction [53].
Conclusion

In conclusion, in this study we investigated that the association of an antiestrogen and a natural compound containing antioxidant and androgen-mimetic substances is a valid, safe and effective therapy for treating men with idiopathic oligoasthenozoospermia.

In fact we have demonstrated that the use of this combination significantly improves the number and the motility of sperms. Furthermore there is an improvement of the pregnancy rate comparing with the group taking just tamoxifen citrate and to placebo recipients.

This treatment protocol is inexpensive, safe, and easy to administer.

References


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:
- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/pharma